• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.磺达肝癸钠在非危重症COVID-19患者中的危害：与依诺肝素的回顾性对照研究
Thromb Res. 2020 Dec;196:395-397. doi: 10.1016/j.thromres.2020.09.024. Epub 2020 Sep 17.
2
COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.COVID-19 相关凝血功能障碍：采用增量剂量的血栓预防策略的血栓形成、出血和死亡率。
Thromb Res. 2020 Dec;196:483-485. doi: 10.1016/j.thromres.2020.10.004. Epub 2020 Oct 15.
3
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.新冠肺炎患者使用磺达肝素钠：一项初步的多中心真实世界经验。
J Cardiovasc Pharmacol. 2020 Oct;76(4):369-371. doi: 10.1097/FJC.0000000000000893.
4
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.COVID-19 重症患者中中剂量与标准剂量预防性抗凝和他汀类药物治疗与安慰剂对照的研究：INSPIRATION/INSPIRATION-S 研究的原理和设计。
Thromb Res. 2020 Dec;196:382-394. doi: 10.1016/j.thromres.2020.09.027. Epub 2020 Sep 24.
5
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.
6
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.急性病成年患者中延长剂量的贝曲沙班与标准剂量依诺肝素所致致命或不可逆事件的比较：APEX试验子研究
J Am Heart Assoc. 2017 Jul 11;6(7):e006015. doi: 10.1161/JAHA.117.006015.
7
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.癌症患者静脉血栓栓塞的治疗：Matisse临床试验的亚组分析
Thromb Haemost. 2009 Apr;101(4):762-9.
8
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.抗Xa监测可提高严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者低分子量肝素的疗效。
Thromb Res. 2020 Dec;196:432-434. doi: 10.1016/j.thromres.2020.09.039. Epub 2020 Oct 8.
9
Comparison of the Effects of Low-Molecular-Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism.低分子肝素与磺达肝癸钠对肺栓塞患者肝功能影响的比较。
J Clin Pharmacol. 2020 Dec;60(12):1671-1678. doi: 10.1002/jcph.1686. Epub 2020 Jul 8.
10
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience.（亚）治疗剂量抗凝剂在非危重症 COVID-19 患者中的危害：来自帕多瓦省的经验。
J Thromb Haemost. 2020 Oct;18(10):2629-2635. doi: 10.1111/jth.15022. Epub 2020 Aug 24.

引用本文的文献

1
Increased Thrombotic Risk in COVID-19: Evidence and Controversy.2019冠状病毒病中血栓形成风险增加：证据与争议
J Clin Med. 2023 Jul 1;12(13):4441. doi: 10.3390/jcm12134441.
2
When Will Fondaparinux Induce Thrombocytopenia?磺达肝癸钠何时会引起血小板减少症？
Bioconjug Chem. 2022 Aug 17;33(8):1574-1583. doi: 10.1021/acs.bioconjchem.2c00316. Epub 2022 Jul 25.
3
Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle.Decavanadate 与 SARS-CoV-2 刺突蛋白的元素相互作用突显了静电在破坏感染周期中的潜在作用。
J Inorg Biochem. 2022 Sep;234:111899. doi: 10.1016/j.jinorgbio.2022.111899. Epub 2022 Jun 9.
4
The Role of Heparin in COVID-19: An Update after Two Years of Pandemics.肝素在新冠疫情中的作用：大流行两年后的最新情况
J Clin Med. 2022 May 30;11(11):3099. doi: 10.3390/jcm11113099.
5
Heparin and SARS-CoV-2: Multiple Pathophysiological Links.肝素与 SARS-CoV-2：多种病理生理学关联。
Viruses. 2021 Dec 11;13(12):2486. doi: 10.3390/v13122486.
6
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP).成人新型冠状病毒肺炎患者在非重症监护病房的临床管理：来自意大利抗感染治疗学会（SITA）和意大利肺病学会（SIP）的指南
Infect Dis Ther. 2021 Dec;10(4):1837-1885. doi: 10.1007/s40121-021-00487-7. Epub 2021 Jul 30.
7
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.内皮功能障碍和免疫血栓形成是 COVID-19 的关键发病机制。
Nat Rev Immunol. 2021 May;21(5):319-329. doi: 10.1038/s41577-021-00536-9. Epub 2021 Apr 6.
8
Fondaparinux and bleeding risk in COVID-19: unsolved question.磺达肝癸钠与新型冠状病毒肺炎的出血风险：未解之谜
Thromb Res. 2021 Apr;200:128-129. doi: 10.1016/j.thromres.2021.01.025. Epub 2021 Feb 9.

本文引用的文献

1
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience.（亚）治疗剂量抗凝剂在非危重症 COVID-19 患者中的危害：来自帕多瓦省的经验。
J Thromb Haemost. 2020 Oct;18(10):2629-2635. doi: 10.1111/jth.15022. Epub 2020 Aug 24.
2
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis.COVID-19 住院非 ICU 患者尽管接受了药物预防血栓形成，但仍有深静脉血栓形成的发生率。
J Thromb Haemost. 2020 Sep;18(9):2358-2363. doi: 10.1111/jth.14992. Epub 2020 Aug 27.
3
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.COVID-19 和凝血：SARS-CoV-2 感染的出血和血栓形成表现。
Blood. 2020 Jul 23;136(4):489-500. doi: 10.1182/blood.2020006520.
4
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.确认 COVID-19 重症 ICU 患者的血栓并发症累积发生率较高：更新分析。
Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.
5
Incidence of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的发生率。
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.
6
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.利伐沙班或依诺肝素用于非主要骨科手术。
N Engl J Med. 2020 May 14;382(20):1916-1925. doi: 10.1056/NEJMoa1913808. Epub 2020 Mar 29.
7
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.新型抗凝剂预防髋膝关节置换术后静脉血栓栓塞的安全性和有效性：一项荟萃分析。
J Arthroplasty. 2017 Feb;32(2):645-652. doi: 10.1016/j.arth.2016.09.033. Epub 2016 Oct 5.
8
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.直接口服抗凝剂预防静脉血栓栓塞症：来自主要临床试验的证据。
Semin Hematol. 2014 Apr;51(2):121-30. doi: 10.1053/j.seminhematol.2014.03.006. Epub 2014 Mar 29.
9
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.一种用于识别住院医疗患者静脉血栓栓塞风险的风险评估模型：帕多瓦预测评分。
J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x.
10
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.磺达肝癸钠预防老年急性内科患者静脉血栓栓塞的疗效和安全性：随机安慰剂对照试验
BMJ. 2006 Feb 11;332(7537):325-9. doi: 10.1136/bmj.38733.466748.7C. Epub 2006 Jan 26.

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.

作者信息

Prandoni Paolo, Cattelan Anna Maria, Carrozzi Laura, Leone Lucia, Filippi Lucia, De Gaudenzi Egidio, Villalta Sabina, Pesavento Raffaele

机构信息

Arianna Foundation, Bologna, Italy.

Department of Medicine, Infectious Diseases Unit, University Hospital of Padua, Italy.

出版信息

Thromb Res. 2020 Dec;196:395-397. doi: 10.1016/j.thromres.2020.09.024. Epub 2020 Sep 17.

DOI:10.1016/j.thromres.2020.09.024
PMID:33007739
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7497738/
Abstract
摘要